Discovery Of CC-90011: A Potent And Selective ... - PubMed
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation- Clipboard
- My Bibliography
- Collections
- Citation manager
Save citation to file
Format: Summary (text) PubMed PMID Abstract (text) CSV Create file CancelEmail citation
Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email CancelAdd to Collections
- Create a new collection
- Add to an existing collection
Add to My Bibliography
- My Bibliography
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons- Yes
- No
Create a file for external citation management software
Create file CancelYour RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link CopyFull text links
American Chemical Society Full text links Actions
CiteCollectionsAdd to Collections- Create a new collection
- Add to an existing collection
Page navigation
- Title & authors
- Abstract
- MeSH terms
- Substances
- Associated data
- LinkOut - more resources
Abstract
Histone demethylase LSDl (KDMlA) belongs to the flavin adenine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammalian biology. Dysregulation and overexpression of LSD1 are hallmarks of a number of human diseases, particularly cancers that are characterized as morphologically poorly differentiated. As such, inhibitors of LSD1 have potential to be beneficial as a cancer therapy. The most clinically advanced inhibitors of LSDl are covalent inhibitors derived from tranylcypromine (TCP). Herein, we report the discovery of a novel series of reversible and selective LSDl inhibitors. Exploration of structure-activity relationships (SARs) and optimization of ADME properties resulted in the identification of clinical candidate CC-90011. CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived xenograft (PDX) SCLC models. CC-90011 is currently in phase 2 trials in patients with first line, extensive stage SCLC (ClinicalTrials.gov identifier: NCT03850067).
PubMed Disclaimer
MeSH terms
- Cell Line, Tumor Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Enzyme Inhibitors / chemistry Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Enzyme Inhibitors / pharmacology* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Histone Demethylases / antagonists & inhibitors* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Humans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Organic Chemicals / chemistry Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Organic Chemicals / pharmacology* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Structure-Activity Relationship Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Substances
- Enzyme Inhibitors Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Organic Chemicals Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- pulrodemstat besilate Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Histone Demethylases Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- KDM1A protein, human Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Associated data
- ClinicalTrials.gov/NCT03850067 Actions
- Search in PubMed
- Search in ClinicalTrials.gov
LinkOut - more resources
Full Text Sources
- American Chemical Society
Other Literature Sources
- The Lens - Patent Citations Database
Chemical Information
- BindingDB
Medical
- ClinicalTrials.gov
Molecular Biology Databases
- Guide to Pharmacology
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal
American Chemical Society [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To - Clipboard
- Save
- My Bibliography
- Collections
- Citation Manager
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Từ khóa » Cc-90011
-
Discovery Of CC-90011: A Potent And Selective Reversible Inhibitor ...
-
A Safety And Efficacy Study Of CC-90011 In Combination With ...
-
Phase I Study Of CC-90011 In Patients With ... - Annals Of Oncology
-
Phase I Study Of Lysine-Specific Demethylase 1 Inhibitor, CC-90011 ...
-
Phase 1/2 Study Investigating CC-90011, A Potent, Selective, And ...
-
Pulrodemstat (CC-90011) Besylate - LSD1 Inhibitor
-
Phase I Study Of CC-90011 In Patients With Advanced Solid Tumors ...
-
A Phase 1b Study Of CC-90011, A Potent, Reversible, Oral LSD1 ...
-
Phase I Study Of CC-90011 In Patients With Advanced Solid Tumours ...
-
Clinical Activity Of CC‐90011, An Oral, Potent, And Reversible LSD1 ...
-
LSD1/KDM1A Inhibitors In Clinical Trials: Advances And Prospects
-
CC-90011 | Ligand Page | IUPHAR/BPS Guide To PHARMACOLOGY
-
Pulrodemstat Benzenesulfonate (CC-90011 ... - MedChemExpress
-
CC-90011-ST-001 - Health Research Authority